Man Group
ATYR

Man Group’s aTyr Pharma ATYR Stock Holding History

Man Group’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,248
Closed -$55.2K – 2411
2024
Q4 		$55.2K Buy
+15,248
New +$46.2K ﹤0.01% 1945
2023
Q3 		– Sell
-306,950
Closed -$568K – 1432
2023
Q2 		$663K Buy
+306,950
New +$670K ﹤0.01% 1504

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Man Group's ATYR Position: Q1 2025 in Review

Man Group sold out of aTyr Pharma (ATYR) in Q1 2025, closing a stake of 15,248 shares — an estimated $55.2K sold.

Man Group first reported a position in ATYR in Q2 2023 and held it in 2 quarters. The position peaked at $663K in Q2 2023. 87 funds tracked by Wall St. Rank hold ATYR as of Q1 2025.

  • Man Group reported no remaining aTyr Pharma position as of Q1 2025 after selling out during the quarter.
  • Man Group sold 15,248 aTyr Pharma shares in Q1 2025, an estimated $55.2K.
  • Man Group first reported a position in aTyr Pharma in Q2 2023 and held it in 2 quarters.
  • Man Group's aTyr Pharma position peaked at $663K in Q2 2023.
  • 87 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2025.

Based on Man Group's 13F filing for Q1 2025, filed 15 May 2025.